Comparative Bioavailability Study of TV-44749 Versus Oral Olanzapine in Schizophrenia Patients

The primary objective of this open-label trial is to assess the comparative **bioavailability** of TV-44749 to oral **olanzapine** in participants with **schizophrenia**. Evaluating the bioavailability is clinically relevant as it determines the extent and rate at which the active drug ingredient is absorbed and becomes available at the site of action, which is crucial for ensuring therapeutic efficacy and safety in treating schizophrenia.

The clinical trial involves a total of **82 participants** diagnosed with **schizophrenia**. The study population includes both male and female subjects, with an age range classified under category code "3," which typically corresponds to adults. Participants were selected to include a vulnerable population, although specific criteria for vulnerability are not detailed. The trial does not specify particular lifestyle considerations such as diet, physical activity, or habits. The sponsor has not provided detailed information regarding the main objective of the trial or the principal inclusion criteria. The selection process aimed to encompass a diverse group of individuals, ensuring a comprehensive understanding of the treatment's effects across different demographics within the specified age range.

The clinical trial is designed to evaluate the **bioavailability** of TV-44749 compared to oral olanzapine in participants diagnosed with **schizophrenia**. This study is structured as an open-label trial, which means that both the researchers and participants are aware of the treatment being administered. The trial is categorized under Phase 3, indicating that it is in the later stages of clinical testing, focusing on the efficacy and monitoring of adverse reactions in a larger participant group. The estimated recruitment start date is April 2, 2024, with an anticipated end date of June 10, 2025, marking the overall trial duration of approximately 14 months.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, to determine eligibility based on predefined criteria. This initial visit will involve assessments to confirm the diagnosis of schizophrenia and ensure that participants meet all necessary inclusion criteria while not falling under any exclusion criteria. Following the inclusion visit, participants will attend scheduled follow-up visits throughout the trial period. These visits are designed to monitor the participants' health, assess the drug's bioavailability, and collect data on any side effects or adverse events. The trial will conclude with an end-of-study visit, where final evaluations will be conducted to gather comprehensive data on the treatment's efficacy and safety.

The expected length of participant involvement in the trial is aligned with the overall trial duration, spanning from the recruitment start date to the end-of-study visit. However, certain conditions may lead to early termination from the study, such as the occurrence of significant adverse events, withdrawal of consent by the participant, or any other medical or ethical reasons deemed necessary by the study investigators. Participants' safety and well-being are prioritized throughout the trial, with continuous monitoring to ensure adherence to ethical standards and regulatory requirements.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a paediatric formulation or if it is classified as an orphan drug. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the study may include the use of non-experimental treatments such as standard-of-care therapy, placebo, or comparator treatment. However, the data does not provide explicit details about these non-experimental treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these treatments is also not available in the provided data.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on April 2, 2024, with an estimated completion date of June 10, 2025. The efficacy assessment will be conducted through a series of pre-defined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The focus will be on evaluating the treatment's impact on the specified medical condition, utilizing appropriate clinical methodologies and tools as per standard Phase 3 trial protocols. The trial will adhere to rigorous scientific standards to ensure the reliability and validity of the efficacy outcomes.